» Articles » PMID: 37529037

Role of Mitochondria-bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Abstract

Background: Glucose metabolism, specifically, hexokinase 2 (HK2), has a critical role in rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) phenotype. HK2 localizes not only in the cytosol but also in the mitochondria, where it protects mitochondria against stress. We hypothesize that mitochondria-bound HK2 is a key regulator of RA FLS phenotype.

Methods: HK2 localization was evaluated by confocal microscopy after FLS stimulation. RA FLSs were infected with Green fluorescent protein (GFP), full-length (FL)-HK2, or HK2 lacking its mitochondrial binding motif (HK2ΔN) expressing adenovirus (Ad). RA FLS was also incubated with methyl jasmonate (MJ; 2.5 mM), tofacitinib (1 µM), or methotrexate (1 µM). RA FLS was tested for migration and invasion and gene expression. Gene associations with HK2 expression were identified by examining single-cell RNA sequencing (scRNA-seq) data from murine models of arthritis. Mice were injected with K/BxN serum and given MJ. Ad-FLHK2 or Ad-HK2ΔN was injected into the knee of wild-type mice.

Results: Cobalt chloride (CoCl) and platelet-derived growth factor (PDGF) stimulation induced HK2 mitochondrial translocation. Overexpression of the HK2 mutant and MJ incubation reversed the invasive and migrative phenotype induced by FL-HK2 after PDGF stimulation, and MJ also decreased the expression of C-X-C Motif Chemokine Ligand 1 (CXCL1) and Collagen Type I Alpha 1 Chain (COL1A1). Of interest, tofacitinib but not methotrexate had an effect on HK2 dissociation from the mitochondria. In murine models, MJ treatment significantly decreased arthritis severity, whereas HK2FL was able to induce synovial hypertrophy as opposed to HK2ΔN.

Conclusion: Our results suggest that mitochondrial HK2 regulates the aggressive phenotype of RA FLS. New therapeutic approaches to dissociate HK2 from mitochondria offer a safer approach than global glycolysis inhibition.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.


Exploring glycolytic enzymes in disease: potential biomarkers and therapeutic targets in neurodegeneration, cancer and parasitic infections.

Rojas-Pirela M, Andrade-Alviarez D, Rojas V, Marcos M, Salete-Granado D, Chacon-Arnaude M Open Biol. 2025; 15(2):240239.

PMID: 39904372 PMC: 11793985. DOI: 10.1098/rsob.240239.


Triglyceride-glucose index in the prediction of new-onset arthritis in the general population aged over 45: the first longitudinal evidence from CHARLS.

Liu Y, Yao J, Xue X, Lv Y, Guo S, Wei P Lipids Health Dis. 2024; 23(1):79.

PMID: 38481325 PMC: 10936084. DOI: 10.1186/s12944-024-02070-8.


Targeting glycolytic pathway in fibroblast-like synoviocytes for rheumatoid arthritis therapy: challenges and opportunities.

Li Q, Chen Y, Liu H, Tian Y, Yin G, Xie Q Inflamm Res. 2023; 72(12):2155-2167.

PMID: 37940690 DOI: 10.1007/s00011-023-01807-y.

References
1.
Pucino V, Certo M, Varricchi G, Marone G, Ursini F, Rossi F . Metabolic Checkpoints in Rheumatoid Arthritis. Front Physiol. 2020; 11:347. PMC: 7180190. DOI: 10.3389/fphys.2020.00347. View

2.
Lunt S, Vander Heiden M . Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-64. DOI: 10.1146/annurev-cellbio-092910-154237. View

3.
Pedersen P, Mathupala S, Rempel A, Geschwind J, Ko Y . Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002; 1555(1-3):14-20. DOI: 10.1016/s0005-2728(02)00248-7. View

4.
Yamaoka K . Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol. 2019; 15(6):577-588. DOI: 10.1080/1744666X.2019.1607298. View

5.
Nakashima R, Paggi M, Scott L, Pedersen P . Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res. 1988; 48(4):913-9. View